AbbVie cuts 2025 adjusted EPS guidance to $9.90-$9.94 on $1.3 billion Q4 IPR&D expense
AbbVie said its fourth-quarter 2025 results will include $1.3 billion in pre-tax acquired IPR&D and milestones expense, which lowers both GAAP and adjusted diluted EPS by $0.71. The company's full-year 2025 adjusted EPS guidance now falls to $9.90-$9.94 from $10.61-$10.65 excluding the charge, and results for the quarter have not been finalized.
- Q4 2025 acquired IPR&D and milestones expense: $1.3 billion pre-tax ($1,265 million), reducing EPS by $0.71
- Full-year 2025 adjusted diluted EPS guidance: $9.90-$9.94, including the Q4 expense, versus $10.61-$10.65 previously announced on October 31, 2025 excluding it
- Q4 2025 adjusted diluted EPS guidance: $2.61-$2.65, versus $3.32-$3.36 before the expense; figures are preliminary and subject to closing procedures